EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">"The Orange Book listing of these two patents covering Phexxi's composition of matter and its method of use in contraception is an important step in further strengthening our patent portfolio," said Evofem Biosciences CEO Saundra Pelletier. Phexxi® is a registered trademark of Evofem Biosciences, Inc. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. All forward-looking statements are expressly qualified in their entirety by such factors. ContactAmy RaskopfSVP, Investor RelationsEvofem Biosciences, Inc.araskopf@evofem.com / media@evofem.com(917) 673-5775View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-announces-fda-orange-book-listing-of-two-additional-us-patents-for-phexxi-301756268.htmlSOURCE Evofem Biosciences, Inc.

Source: Washington Post June 27, 2024 17:28 UTC